半乳糖凝集素-3 (GAL-3)及可溶性生长刺激表达基因2蛋白(sST2)在STEMI患者PCI术后并发急性心力衰竭中的研究进展
Research Progress of GAL-3 and sST2 in Acute Heart Failure after PCI in STEMI Patients
摘要: 本研究对半乳糖凝集素-3 (GAL-3)和可溶性生长刺激表达基因2蛋白(sST2)在急性ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)后急性心力衰竭(AHF)发生发展中的临床应用价值进行了叙述性综述。这两种新型生物标志物在心肌纤维化和心室重构的病理生理过程中发挥着关键调控作用。本文详细探讨了半乳糖凝集素-3 (GAL-3)和可溶性生长刺激表达基因2蛋白(sST2)的分子结构特征、表达调控机制、动态变化模式及其临床预测效能，重点评估了联合检测的协同效应。同时，深入剖析了基于这些标志物的风险分层体系构建、治疗监测策略优化以及个体化治疗方案制定的应用前景，并对当前研究中的技术瓶颈和未来发展方向进行了全面阐述。
Abstract: This study conducted a systematic analysis of the clinical application value of galactose lectin-3 (GAL-3) and soluble growth factor expression gene 2 protein (sST2) in the pathogenesis of acute heart failure (AHF) following percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI). These novel biomarkers play critical regulatory roles in the pathophysiological processes of myocardial fibrosis and ventricular remodeling. The paper provides a detailed exploration of the molecular structural characteristics, expression regulation mechanisms, dynamic patterns, and clinical predictive efficacy of GAL-3 and sST2, with particular emphasis on evaluating their synergistic effects when detected jointly. Additionally, it thoroughly examines the potential applications for constructing risk stratification systems, optimizing therapeutic monitoring strategies, and developing personalized treatment plans based on these biomarkers. The study also comprehensively addresses current technical challenges and outlines future research directions in this field.
文章引用：李慧, 王营忠. 半乳糖凝集素-3 (GAL-3)及可溶性生长刺激表达基因2蛋白(sST2)在STEMI患者PCI术后并发急性心力衰竭中的研究进展[J]. 临床医学进展, 2025, 15(9): 347-351. https://doi.org/10.12677/acm.2025.1592496

参考文献

[1] Fu, B., Wei, X., Wang, Q., Yang, Z., Chen, J. and Yu, D. (2021) Use of the Thrombolysis in Myocardial Infarction Risk Index for Elderly Patients with ST-Segment Elevation Myocardial Infarction. Frontiers in Cardiovascular Medicine, 8, Article ID: 743678. [Google Scholar] [CrossRef] [PubMed]
[2] Kröpfl, J.M., Beltrami, F.G., Gruber, H., Schmidt‐Trucksäss, A., Dieterle, T. and Spengler, C.M. (2023) Circulating Gal‐3 and sST2 Are Associated with Acute Exercise‐Induced Sustained Endothelial Activation: Possible Relevance for Fibrosis Development? Experimental Physiology, 108, 1259-1267. [Google Scholar] [CrossRef] [PubMed]
[3] Lima, T., Perpétuo, L., Henrique, R., Fardilha, M., Leite-Moreira, A., Bastos, J., et al. (2022) Galectin-3 in Prostate Cancer and Heart Diseases: A Biomarker for These Two Frightening Pathologies? Molecular Biology Reports, 50, 2763-2778. [Google Scholar] [CrossRef] [PubMed]
[4] Dudek, M., Kałużna-Oleksy, M., Migaj, J., Sawczak, F., Krysztofiak, H., Lesiak, M., et al. (2023) sST2 and Heart Failure—Clinical Utility and Prognosis. Journal of Clinical Medicine, 12, Article No. 3136. [Google Scholar] [CrossRef] [PubMed]
[5] Cao, Z., Yu, X. and Leng, P. (2021) Research Progress on the Role of Gal-3 in Cardio/Cerebrovascular Diseases. Biomedicine & Pharmacotherapy, 133, Article ID: 111066. [Google Scholar] [CrossRef] [PubMed]
[6] Agnello, L., Bivona, G., Lo Sasso, B., Scazzone, C., Bazan, V., Bellia, C., et al. (2017) Galectin-3 in Acute Coronary Syndrome. Clinical Biochemistry, 50, 797-803. [Google Scholar] [CrossRef] [PubMed]
[7] Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G., et al. (2018) Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. International Journal of Molecular Sciences, 19, Article No. 379. [Google Scholar] [CrossRef] [PubMed]
[8] Gao, Z., Liu, Z., Wang, R., Zheng, Y., Li, H. and Yang, L. (2020) Galectin-3 Is a Potential Mediator for Atherosclerosis. Journal of Immunology Research, 2020, Article ID: 5284728. [Google Scholar] [CrossRef] [PubMed]
[9] Salvagno, G.L. and Pavan, C. (2016) Prognostic Biomarkers in Acute Coronary Syndrome. Annals of Translational Medicine, 4, Article No. 258. [Google Scholar] [CrossRef] [PubMed]
[10] Pascual-Figal, D.A., Lax, A., Perez-Martinez, M.T., del Carmen Asensio-Lopez, M., Sanchez-Mas, J. and on Behalf of GREAT Network (2016) Clinical Relevance of sST2 in Cardiac Diseases. Clinical Chemistry and Laboratory Medicine (CCLM), 54, 29-35. [Google Scholar] [CrossRef] [PubMed]
[11] Huang, S., Wei, Q., Zhi, X., Wang, J. and Zhang, Z. (2020) Application Value of Serum sST2 in Diagnosis and Prognosis of Heart Failure. Chinese Journal of Biotechnology, 36, 1713-1722.
[12] Barutaut, M., Fournier, P., Peacock, W.F., Evaristi, M., Dambrin, C., Caubère, C., et al. (2019) sST2 Adds to the Prognostic Value of Gal-3 and BNP in Chronic Heart Failure. Acta Cardiologica, 75, 739-747. [Google Scholar] [CrossRef] [PubMed]
[13] Timothy, S.D., Hartopo, A.B., Anggraeni, V.Y. and Makrufardi, F. (2021) Association of Soluble ST2 and Infarct Location within 12-24 h in STEMI: A Cross-Sectional Study. Annals of Medicine and Surgery, 70, Article ID: 102844. [Google Scholar] [CrossRef] [PubMed]
[14] Tymińska, A., Kapłon-Cieślicka, A., Ozierański, K., Budnik, M., Wancerz, A., Sypień, P., et al. (2019) Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after St-Segment Elevation Myocardial Infarction. Disease Markers, 2019, Article ID: 9529053. [Google Scholar] [CrossRef] [PubMed]
[15] Xing, J., Liu, J. and Geng, T. (2021) Predictive Values of sST2 and IL-33 for Heart Failure in Patients with Acute Myocardial Infarction. Experimental Biology and Medicine (Maywood), 246, 2480-2486. [Google Scholar] [CrossRef] [PubMed]
[16] Sun, Y., Huang, X., Hu, B., Wu, Z., Zhang, Y., Yuan, Y., et al. (2025) The Effects of Early Exercise on Cardiovascular Biomarkers in Patients with Congestive Heart Failure. ESC Heart Failure, 12, 2985-2992. [Google Scholar] [CrossRef] [PubMed]
[17] Aleksova, A., Paldino, A., Beltrami, A.P., Padoan, L., Iacoviello, M., Sinagra, G., et al. (2019) Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome—There Is Meat on the Bone. Journal of Clinical Medicine, 8, Article No. 270. [Google Scholar] [CrossRef] [PubMed]
[18] Al Ali, L., Meijers, W.C., Beldhuis, I.E., Groot, H.E., Lipsic, E., van Veldhuisen, D.J., et al. (2024) Association of Fibrotic Markers with Diastolic Function after STEMI. Scientific Reports, 14, Article No. 19122. [Google Scholar] [CrossRef] [PubMed]
[19] O’Donoghue, M.L., Morrow, D.A., Cannon, C.P., Jarolim, P., Desai, N.R., Sherwood, M.W., et al. (2016) Multimarker Risk Stratification in Patients with Acute Myocardial Infarction. Journal of the American Heart Association, 5, e002586. [Google Scholar] [CrossRef] [PubMed]
[20] Tymińska, A., Kapłon-Cieślicka, A., Ozierański, K., Budnik, M., Wancerz, A., Sypień, P., et al. (2019) Association of Galectin-3 and Soluble ST2 with Outcomes in STEMI. Polish Archives of Internal Medicine, 129, 770-780.

为你推荐